ARCHIVES

ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay

This article is from The Cancer Letter archive.

Vol. 35 No. 28 | July 17, 2009

Download PDF Visit The Full Archive

Related Articles

Letter To the Editor: Screening Revisited

May 20, 1994

In Congress: Tamoxifen Results Well Communicated, Understood, NCI Says

May 1, 1998

ASCO Selects Three Cities For Quality Of Care Study.

June 2, 2000

RTOG Finds Twice A Day Radiation For Advanced Head And Neck Cancer Improved Local Tumor Control Rate

August 25, 2000

Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial

December 27, 2013

ASCO Recommends End of Life Discussions

January 28, 2011